Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phosphodiesterase PDE4 inhibitors patented byTakeda

May 11, 2018

LogicBio Therapeutics begins program for genome-editing therapy for methylmalonic acidemia

May 11, 2018

Lipocine receives FDA complete response letter for Tlando

May 10, 2018

Dare Bioscience enters agreement with Pear Tree Pharmaceuticals to secure rights to PT-101

May 9, 2018

MenoGeniX receives grant from NIA for drug to treat menopausal hot flashes

May 7, 2018

OTL-200 receives rare pediatric disease designation from the FDA

May 4, 2018

TES Pharma discovers ACMSD inhibitors

May 3, 2018

FDA grants fast track designation to RGX-121 gene therapy

May 3, 2018

Hanmi opens first-in-human trial of HM-15211 in healthy obese subjects

May 3, 2018

YW-1128, a WNT pathway inhibitor, shows promising in vivo results for metabolic disorders

May 3, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...